[Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible

Andreas J Rieth1,2, Christian W Hamm3,4,5, Christoph Wanner6

  • 1Kerckhoff-Klinik, Abteilung für Kardiologie, Campus Kerckhoff der Justus-Liebig-Universität Gießen, Benekestr. 2-8, 61231, Bad Nauheim, Deutschland. a.rieth@kerckhoff-klinik.de.

Herz
|October 12, 2020
PubMed
Abstract

Insights

Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer moderate heart failure protection in diabetic patients. Mechanisms may involve kidney protection and cardiorenal interaction, requiring further study.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Sodium-glucose cotransporter-2 (SGLT2) inhibitors demonstrate cardioprotective effects beyond their antidiabetic properties.
  • The precise mechanisms underlying these cardiovascular benefits remain largely undetermined.

Purpose of the Study:

  • To investigate the cardioprotective effects of SGLT2 inhibitors, focusing on heart failure endpoints.
  • To explore potential mechanisms of action for the observed cardioprotective effects.

Main Methods:

  • A targeted literature search was conducted in PubMed.
  • The search focused on studies reporting heart failure outcomes and potential SGLT2 inhibitor mechanisms.

Main Results:

  • Treatment with certain SGLT2 inhibitors reduced heart failure hospitalizations compared to placebo, though numbers needed to treat were substantial (72-117).
  • More pronounced weight loss and blood pressure reduction were observed with SGLT2 inhibitors.
  • A correlation was found between the preventive effect and more severe renal impairment.

Conclusions:

  • SGLT2 inhibitors provide a moderate protective effect against heart failure in diabetic individuals.
  • Nephroprotective actions and modulation of cardiorenal interactions are likely key mechanisms.
  • Further research is necessary to confirm these findings and elucidate the underlying pathways.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
119
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
717
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
496
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
483
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
656